TY - JOUR
T1 - Therapeutic Strategies to Prevent the Recurrence of Nasal Polyps after Surgical Treatment: An Update and In Vitro Study on Growth Inhibition of Fibroblasts
AU - Rizzi, Angela
AU - Gammeri, Luca
AU - Cordiano, Raffaele
AU - Valentini, Mariagrazia
AU - Centrone, Michele
AU - Marrone, Sabino
AU - Inchingolo, Riccardo
AU - Lohmeyer, Franziska Michaela
AU - Cavaliere, Carlo
AU - Ria, Francesco
AU - Cadoni, Gabriella
AU - Gangemi, Sebastiano
AU - Nucera, Eleonora
PY - 2023
Y1 - 2023
N2 - Chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis, which is typically characterized by a Type 2 inflammatory reaction, comorbidities and high rates of nasal polyp recurrence, causing severe impact on quality of life. Nasal polyp recurrence rates, defined as the number of patients undergoing revision endoscopic sinus surgery, are 20% within a 5 year period after surgery. The cornerstone of CRSwNP management consists of anti-inflammatory treatment with local corticosteroids. We performed a literature review regarding the therapeutic strategies used to prevent nasal polyp recurrence after surgical treatment. Finally, we report an in vitro study evaluating the efficacy of lysine-acetylsalicylic acid and other non-steroidal anti-inflammatory drugs (ketoprofen and diclofenac) on the proliferation of fibroblasts, obtained from nasal polyp tissue samples. Our study demonstrates that diclofenac, even more so than lysine-acetylsalicylic acid, significantly inhibits fibroblast proliferation and could be considered a valid therapeutic strategy in preventing CRSwNP recurrence.
AB - Chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis, which is typically characterized by a Type 2 inflammatory reaction, comorbidities and high rates of nasal polyp recurrence, causing severe impact on quality of life. Nasal polyp recurrence rates, defined as the number of patients undergoing revision endoscopic sinus surgery, are 20% within a 5 year period after surgery. The cornerstone of CRSwNP management consists of anti-inflammatory treatment with local corticosteroids. We performed a literature review regarding the therapeutic strategies used to prevent nasal polyp recurrence after surgical treatment. Finally, we report an in vitro study evaluating the efficacy of lysine-acetylsalicylic acid and other non-steroidal anti-inflammatory drugs (ketoprofen and diclofenac) on the proliferation of fibroblasts, obtained from nasal polyp tissue samples. Our study demonstrates that diclofenac, even more so than lysine-acetylsalicylic acid, significantly inhibits fibroblast proliferation and could be considered a valid therapeutic strategy in preventing CRSwNP recurrence.
KW - biological therapies
KW - chronic rhinosinusitis with nasal polyps
KW - diclofenac
KW - fibroblast
KW - surgical polypectomy
KW - ketoprofen
KW - lysine-acetylsalicylate
KW - non-steroidal anti-inflammatory drugs
KW - proliferation
KW - intranasal corticosteroids
KW - biological therapies
KW - chronic rhinosinusitis with nasal polyps
KW - diclofenac
KW - fibroblast
KW - surgical polypectomy
KW - ketoprofen
KW - lysine-acetylsalicylate
KW - non-steroidal anti-inflammatory drugs
KW - proliferation
KW - intranasal corticosteroids
UR - http://hdl.handle.net/10807/239595
U2 - 10.3390/jcm12082841
DO - 10.3390/jcm12082841
M3 - Article
SN - 2077-0383
VL - 12
SP - 2841
EP - 2841
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
ER -